Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 19/20 | 1.00 |
| ▸ | NSD2 | O96028 | 3/20 | 1.00 |
| ▸ | NSD3 | Q9BZ95 | 3/20 | 1.00 |
| ▸ | EHMT1 | Q9H9B1 | 3/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 1.00 |
| ▸ | KDM1A | O60341 | 1/20 | 1.00 |
| ▸ | MTOR | P42345 | 1/20 | 1.00 |
| ▸ | RAB9A | P51151 | 1/20 | 1.00 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.93 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29351415 | 1.00 | EHMT2 (1.00) | EHMT2NSD2NSD3EHMT1NPC1 | |
| Water SCHEMBL21610936 | 0.99 | EHMT2 (0.98) | EHMT2NSD2NSD3EHMT1NPC1 | |
| Hydrochloric Acid SCHEMBL20535174 | 0.99 | EHMT2 (1.00) | EHMT2NSD2NSD3EHMT1NPC1 | |
| Hydrochloric Acid SCHEMBL2595237 | 0.99 | EHMT2 (1.00) | EHMT2NSD2NSD3EHMT1NPC1 | |
| Hydrochloric Acid SCHEMBL29849313 | 0.99 | EHMT2 (1.00) | EHMT2NSD2NSD3EHMT1NPC1 | |
| Hydrochloric Acid SCHEMBL15668608 | 0.98 | EHMT2 (0.98) | EHMT2NSD2NSD3EHMT1NPC1 | |
| SCHEMBL14940754 | 0.97 | EHMT2 (1.00) | EHMT2NSD2NSD3EHMT1NPC1 | |
| SCHEMBL15280407 | 0.95 | EHMT2 (0.94) | EHMT2NSD2NSD3EHMT1NPC1 | |
| SCHEMBL21593815 | 0.94 | EHMT2 (0.88) | EHMT2NSD2NSD3EHMT1NPC1 | |
| SCHEMBL15280410 | 0.93 | EHMT2 (0.98) | EHMT2NSD2NSD3EHMT1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 243 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250160275-A1 | COMPOUNDS FOR MODIFYING MEIOTIC RECOMBINATION AND METHODS RELATING THERETO | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2025-05-22 | — | — | US | claimed |
| WO-2024211130-A1 | METHODS FOR MODIFYING MEIOTIC RECOMBINATION IN PLANTS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2024-10-10 | — | — | WO | claimed |
| US-20230364153-A1 | METHOD FOR DIRECT REPROGRAMMING FROM SOMATIC CELLS INTO PANCREATIC BETA CELLS BY USING MICRORNA, AND DIFFERENTIATION COMPOSITION | Research & Business Foundation Sungkyunkwan University (KR) | 2023-11-16 | — | — | US | claimed |
| WO-2023164606-A1 | COMPOUNDS FOR MODIFYING MEIOTIC RECOMBINATION AND METHODS RELATING THERETO | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2023-08-31 | — | — | WO | claimed |
| US-20230218631-A1 | G9A INHIBITION DECREASES STRESS-INDUCED AND DEPENDENCE-INDUCED ESCALATION OF ALCOHOL DRINKING | MUSC FOUND FOR RES DEV (US) | 2023-07-13 | — | — | US | claimed |
| WO-2022229932-A1 | HYPOXIA INDUCIBLE FACTOR (HIF) INHIBITORS FOR TREATMENT OF ATROPHY ASSOCIATED WITH RETINAL HYPOXIA | STEFANSSON EINAR (IS) | 2022-11-03 | — | — | WO | claimed |
| WO-2022065859-A1 | METHOD FOR DIRECT REPROGRAMMING FROM SOMATIC CELLS INTO PANCREATIC BETA CELLS BY USING MICRORNA, AND DIFFERENTIATION COMPOSITION | 성균관대학교산학협력단 | 2022-03-31 | — | — | WO | claimed |
| WO-2022016097-A1 | G9A INHIBITION DECREASES STRESS-INDUCED AND DEPENDENCE-INDUCED ESCALATION OF ALCOHOL DRINKING | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2022-01-20 | — | — | WO | claimed |
| US-20210213014-A1 | METHODS OF USING EHMT2 INHIBITORS IN IMMUNOTHERAPIES | Epizyme, Inc. | 2021-07-15 | — | — | US | claimed |
| US-20210198277-A1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS | Epizyme, Inc. | 2021-07-01 | — | — | US | claimed |
| US-20200054635-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | Epizyme, Inc. | 2020-02-20 | — | — | US | claimed |
| CN-110621316-A | Combination therapy with EHMT2 inhibitors | EPIZYME股份有限公司 | 2019-12-27 | — | — | CN | claimed |
| EP-3442947-A1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS AS EHMT1 AND EHMT2 INHIBITORS | Epizyme Inc (US) | 2019-02-20 | — | — | EP | claimed |
| WO-2018195450-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | Epizyme, Inc. (US) | 2018-10-25 | — | — | WO | claimed |
| US-20170355712-A1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS | Epizyme, Inc. | 2017-12-14 | — | — | US | claimed |
| WO-2017181177-A1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS AS EHMT1 AND EHMT2 INHIBITORS | Epizyme, Inc. (US) | 2017-10-19 | — | — | WO | claimed |
| US-20150259649-A1 | CELLULAR COMPOSITIONS USED TO RESTORE STEM CELL OR PROGENITOR CELL FUNCTION AND METHODS RELATED THERETO | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-09-17 | — | — | US | claimed |
| US-20140294764-A1 | COMPOUNDS AND COMPOSITIONS USED TO EPIGENETICALLY TRANSFORM CELLS AND METHODS RELATED THERETO | ISTITUTO PASTEUR - FONDAZIONE CENCI BOLOGNETTI (IT) | 2014-10-02 | — | — | US | claimed |
| WO-2014074517-A1 | CELLULAR COMPOSITIONS USED TO RESTORE STEM CELL OR PROGENITOR CELL FUNCTION AND METHODS RELATED THERETO | EMORY UNIVERSITY (US) | 2014-05-15 | — | — | WO | claimed |
| WO-2013070852-A2 | COMPOUNDS AND COMPOSITIONS USED TO EPIGENETICALLY TRANSFORM CELLS AND METHODS RELATED THERETO | EMORY UNIVERSITY (US) | 2013-05-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355712-A1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS | SHMT1, BHMT, BHMT2 | EHMT2 4/4885NSD2 136/4885NSD3 121/4885 |
| US-20210198277-A1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS | SHMT1, BHMT, BHMT2 | EHMT2 4/4885NSD2 136/4885NSD3 121/4885 |
| US-20230218631-A1 | G9A INHIBITION DECREASES STRESS-INDUCED AND DEPENDENCE-INDUCED ESCALATION OF ALCOHOL DRINKING | EHMT2, EHMT1, KMT2A | EHMT2 1/4885NSD2 160/4885NSD3 76/4885 |
| US-20200054635-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | EHMT2, BHMT, SHMT2 | EHMT2 1/4885NSD2 144/4885NSD3 312/4885 |
| US-20140294764-A1 | COMPOUNDS AND COMPOSITIONS USED TO EPIGENETICALLY TRANSFORM CELLS AND METHODS RELATED THERETO | BMI1, DNMT3L, DNMT3B | EHMT2 8/4885NSD2 265/4885NSD3 94/4885 |
| US-20150259649-A1 | CELLULAR COMPOSITIONS USED TO RESTORE STEM CELL OR PROGENITOR CELL FUNCTION AND METHODS RELATED THERETO | BMI1, DNMT1, DNMT3A | EHMT2 8/4885NSD2 1028/4885NSD3 277/4885 |
| US-20210213014-A1 | METHODS OF USING EHMT2 INHIBITORS IN IMMUNOTHERAPIES | EHMT2, BHMT2, BHMT | EHMT2 1/4885NSD2 449/4885NSD3 727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.